Novel approaches for therapy of chronic hepatitis C.
Currently available anti-HCV therapy is effective in only half of the patients and limited by side effects that often necessitate discontinuation. Therefore, new treatment strategies are being developed including (i) the optimization of current regimens, (ii) the use of additional agents working via novel mechanisms, and (iii) anti-fibrotic strategies. Many new antiviral compounds are now being studied in preclinical and clinical trials. This review will focus on drugs that have already entered the stage of phase 2 or phase 3 studies.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. rudolf.stauber@meduni-graz.at
Rudolf E
RE
Stauber
Vanessa
V
Stadlbauer
D000928:Antidepressive Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000627:therapeutic use; D016679:Genome, Viral; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D011480:Protease Inhibitors / Q000627:therapeutic use; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000627:therapeutic use; D011741:Pyrimidine Nucleosides / Q000627:therapeutic use; D012254:Ribavirin / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use
D000928:Antidepressive Agents; D000998:Antiviral Agents; D011480:Protease Inhibitors; D011741:Pyrimidine Nucleosides; D014761:Viral Hepatitis Vaccines; D004921:Erythropoietin; D012254:Ribavirin; D007372:Interferons; D011683:Purine-Nucleoside Phosphorylase; C506207:valopicitabine; C026956:taribavirin